Archive: 2014

 

 

Nexvet Announces Collaboration and Distribution Agreement with Virbac

Veterinary biologic therapy developer Nexvet Biopharma today announced the signing of a ten year collaboration and distribution agreement with Virbac (EPA:VIRP), one of the largest animal health dedicated companies in the world. 

Read more about Nexvet Announces Collaboration and Distribution Agreement with Virbac

SeaDragon Investor Update November 2014

4 November 2014. Link here.

Read more about SeaDragon Investor Update November 2014

Rex Bionics was winner of ‘Best Technology Award’ at the AIM Awards 2014

Link here.

Read more about Rex Bionics was winner of ‘Best Technology Award’ at the AIM Awards 2014

SeaDragon strengthens leadership team

New Zealand’s largest refiner and blender of high-quality fish oils SeaDragon today announced it has expanded its leadership team with the appointment of a permanent Chief Financial Officer, a Director of Sales, a Head of Marketing and a Compliance Co-ordinator.

Read more about SeaDragon strengthens leadership team

Nexvet – Two industry leaders join the Board of Directors

Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr. Ashraf Hanna, M.D., Ph.D., and Dr. Joseph McCracken D.V.M., M.S., to its Board of Directors. Dr. Hanna is the Vice President of Commercial and Medical Affairs Finance at Genentech and Chief Financial Officer for the Genentech Foundation, while Dr. McCracken most recently served as Vice President and Global Head of Business Development and Licensing for Roche Pharma.

Read more about Nexvet – Two industry leaders join the Board of Directors

Nexvet expands veterinary biologics research team

Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team.

Read more about Nexvet expands veterinary biologics research team

SeaDragon 2014 Annual Meeting Results and Determinations

The following resolutions were put to shareholders of SeaDragon Limited at its Annual Meeting held yesterday.

Read more about SeaDragon 2014 Annual Meeting Results and Determinations

BioScience Managers Capital Return on Healthcare Fund I Locks in 24.7% IRR for Investors

Leading Australian healthcare fund manager Bioscience Managers has maintained its exceptional performance by returning capital to investors from its Australian Bioscience Fund I at 24.7% annual IRR.

Read more about BioScience Managers Capital Return on Healthcare Fund I Locks in 24.7% IRR for Investors

Rex Bionics awarded major research & development grant by NZ Government

Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces that its Auckland-based subsidiary Rex Bionics Ltd (RBL) has been awarded substantial new grant funding by the New Zealand Government to support the research and development of REX 3, the platform for the Company’s next generation of exoskeletons.

Read more about Rex Bionics awarded major research & development grant by NZ Government

Rex Bionics: Appointment of Crispin Simon as CEO

Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces the appointment of Crispin Simon as Chief Executive Officer.

Read more about Rex Bionics: Appointment of Crispin Simon as CEO

1 2 3 4